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Abstract Liposomes are versatile (sub)micron-sized mem-
brane vesicles that can be used for a variety of applications,
including drug delivery and in vivo imaging but they also
represent excellent models for artiﬁcial membranes or cells.
Several studies have demonstrated that in vitro transcription
and translation can take place inside liposomes to obtain
compartmentalized production of functional proteins within
the liposomes(Kitaetal. in Chembiochem 9(15):2403–2410,
2008; Moritani et al.in FEBS J, 2010;K u r u m ae ta l .i n
Methods Mol Biol 607:161–171, 2010; Murtas et al. in Bio-
chem Biophys Res Commun 363(1):12–17, 2007; Sunami
et al. in Anal Biochem 357(1):128–136, 2006;I s h i k a w ae ta l .
in FEBS Lett 576(3):387–390, 2004; Oberholzer et al. in
BiochemBiophysResCommun261(2):238–241,1999).Such
a minimal artiﬁcial cell-based model is ideal for synthetic
biologybasedapplications.Inthisstudy,weproposetheuseof
liposomes as artiﬁcial microbes for vaccination. These artiﬁ-
cial microbes can be genetically programmed to produce
speciﬁc antigens at will. To show proof-of-concept for this
artiﬁcial cell-based platform, a bacterial in vitro transcription
andtranslationsystemtogetherwithageneconstructencoding
the model antigen b-galactosidase were entrapped inside
multilamellar liposomes.Vaccinationstudiesinmiceshowed
that such antigen-expressing immunostimulatory liposomes
(AnExILs)elicitedhigherspeciﬁchumoralimmuneresponses
against the produced antigen (b-galactosidase) than control
vaccines (i.e. AnExILs without genetic input, liposomal
b-galactosidase or pDNA encoding b-galactosidase).
In conclusion, AnExILs present a new platform for DNA-
based vaccines which combines antigen production, adju-
vanticity and delivery in one system and which offer several
advantages over existing vaccine formulations.
Keywords Synthetic biology   Cell-free protein
synthesis   Vaccine   DNA vaccination
Introduction
Synthetic biology is a rapidly emerging interdisciplinary
researchﬁeld that aims toconstructnew biological parts and
systems with new functionalities through a process of engi-
neeringandstandardization.Vaccinesmayalsobeneﬁtfrom
a synthetic biology-based design. With vaccination the aim
is to delude the immune system with an antigenic formula-
tion to make it believe it is dealing with a natural infection,
however,without causing illness. At present, the majority of
vaccines on the market consist of attenuated or inactivated
pathogens. Although effective, these systems are poorly
deﬁned,sufferfrombatch-to-batchvariationandcanonlybe
used for pathogens that can be readily cultivated in the lab at
scales thatpermitvaccineproduction. Moreover,astheratio
of antigenic compounds within the pathogen is more-or-less
ﬁxed, there is poor control over the direction against which
antigeniccompoundanimmunereactionwillbeevoked.The
bottom-up design of vaccines which consist of well-deﬁned
antigenic compounds (e.g. proteins or nucleic acids) offers
better control over the evoked immune reaction, however,
the design of such vaccines is often empirical and in general
yields vaccines that are poorly immunogenic and rely on
adjuvants in order to be effective. Moreover, most vaccine
production schemes are rather time-consuming, and there-
fore not suitable for rapid response intervention, for
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strain in the human population.
Cell-free synthetic biology may offer new ways to design
potent and genetically programmable vaccines (Jewett et al.
2008;Tsuboietal.2008,2010a,b;Zicheletal.2010;Kanter
et al. 2007; Simpson 2006). It is based on the in vitro tran-
scriptionandtranslationofsingleormultiplegeneconstructs
inordertoobtainafunctionalpartorsystem.Applicationsof
cell-free biology include the production of membrane pro-
teins that are difﬁcult to express in heterologous hosts
(Henderson et al. 2007; Junge et al. 2010; Beebe et al. 2010;
Nozawa et al. 2010; Reckel et al. 2010; Ishihara et al. 2005;
Berrier et al. 2004), high-throughput screening of protein
libraries by in vitro compartmentalization (Mastrobattista
et al. 2005), generation of artiﬁcial cells by encapsulation of
these complex biochemical reactions into cell-sized com-
partments, like liposomes (Kita et al. 2008; Sunami et al.
2006,2010;Yamaji etal.2009;Murtas etal.2007;Ishikawa
etal.2004;Oberholzeretal.1999).Recently,wehaveshown
that protein expression in liposomes can yield microgram-
quantities of a model antigen (Amidi et al. 2010).
In this study, we propose the use of antigen-expressing
immunostimulatory liposomes (AnExILs) as artiﬁcial
microbes for vaccination (Fig. 1). The potential advantages
of such antigen-expressing immunostimulatory liposomes
(AnExILs) over conventional vaccines are numerous: the
speciﬁcity of the vaccine can be easily altered by simply
changing the DNA templates without having to change the
entire vaccine formulation. Moreover, compared to DNA
vaccines AnExILs do not exclusively rely on the often
inefﬁcient transfection of DNA into cells of the vaccine
recipient in order to be effective. Secondly, compared to
vector-based vaccines, AnExILs will be unaffected by
neutralizing antibodies against the vector. Thirdly, there is
no limit to the number of genes that can be expressed inside
AnExILs. Lastly, AnExILs mimic characteristics of viruses
and bacteria without the safety concerns related to the use of
attenuated pathogens for vaccination. Here, we show that
AnExILs expressing b-galactosidase are well tolerated after
i.m. injection and were capable of inducing strong systemic
immune responses, which were superior to that of liposomal
DNA or protein vaccines encoding the same antigen.
Materials and methods
Materials
Egg-derived L-a-phosphatidylcholine (EPC), 1,2-distea-
royl-sn-glycero-3-phosphoethanolamine-polyethylene glycol
(PEG)5000(DSPE-PEG5000)and1,2-dioleoyl-sn-glycero-
3-([N(5-amino-1-carboxypentyl) iminodi-acetic acid] suc-
cinyl) (DOGS-NTA) were purchased from Avanti Polar
Lipids, Inc. (Alabaster, Alabama, USA). Luria Broth, 2-
mercaptoethanol, adenosine-50-triphosphate (ATP), phos-
phoenol-pyruvate (PEP), cytidine-50-triphosphate (CTP),
guanosine-50-triphosphate (GTP), 30-50-cyclic adenosine
monophosphate (cAMP), folinic acid, cholesterol (CHOL)
and b-galactosidase enzyme (400 IU/mg) and each of the 20
encoded amino acids were purchased from Sigma (Saint
Louis,MO,USA).TheFluoresceindi-b-D-galactopyranoside
(FDG) was supplied from Marker Gene Technologies
(Eugene, OR, USA). E-coli tRNA, creatine kinase and crea-
tine phosphate were obtained from Roche (Basel, Switzer-
land). Uridine 50-triphosphate (UTP) and T7 polymerase
were supplied from Fermentas (Burlington, Ontario, Can-
ada). Dithiothreitol (DTT), Lysogeny broth (LB) and pyru-
vate kinase (PK) were from Flucka (Seelze, Germany).
Rabbit polyclonal anti-b-galactosidase IgG and Cy-5 conju-
gatedgoatIgGanti-rabbitimmunoglobulinwasfromAbcam
(Cambridge, UK). Horseradish Peroxidase (HRP)-labeled
goatanti-mousetotalIgGandHRP-labeledrabbitanti-mouse
IgG1 were purchased from Invitrogen (Breda, The Nether-
lands). HRP-labeled Rat monoclonal anti-mouse IgG2a was
obtained from Abcam (Cambridge, The United Kingdom).
PEG8000wasfromPromega(Madison,WI,USA).Allother
materials used were of analytical or pharmaceutical grade.
Preparation of PEG-liposomes and Ni
2? NTA
liposomes
A mixture of 2.5 lmol of total lipids (EPC, CHOL and
DSPE-PEG 5000 with a molar ratio of EPC:CHOL:PEG
Fig. 1 Schematic representation of AnExIL formulations used in this
study
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1235000 = 1.6:0.9:0.025) or (EPC, CHOL, DOGS-NTA) with
a molar ratio of EPC:CHOL:DOGS-NTA = 1.55:0.9:
0.025) were dissolved in dichloromethane:diethylether
(1:1, v/v) in a round bottom ﬂask. A thin, dry lipid ﬁlm was
obtained after evaporating the solvents using a rotary
evaporator under vacuum at 30C and subsequently dried
with nitrogen for 30 min. The lipid ﬁlm was hydrated in
distilled water by shaking using glass beads to form large
multilamellar liposomes, further sonicated with a probe
sonicator to produce unilamellar liposomes. The liposomes
suspensions were divided into 100 ll aliquots in 1.5 ml
tubes (6 lm of total lipids/batch), freeze-dried and the
obtained lyophilized lipid cakes were stored in a desiccator
at room temperature until used.
Characterization of liposome formulations
Volume-weighted mean diameters and size distributions of
the liposomes were determined by single particle optical
sensing (Accusizer
TM 780, Santa Barbara, California,
USA).
Cell-free protein expression
For cell-free protein expression, E. coli b-galactosidase
was used as a model antigen. LacZ, encoding E. coli
b-galactosidase was cloned into vector pIVEX2.2EM,
which allowed T7 promoter-driven expression in pro-
karyotic cell-free transcription and translation systems.
The vector appends a 6-histidine (6-HIS) coding sequence
to the C-terminal end of lacZ for efﬁcient puriﬁcation of
the b-galactosidase protein (Amidi et al. 2010). The E.coli
Tuner
TM strain, which is devoid of endogenous b-galac-
tosidase (Merck Chemicals Ltd., Nottingham, UK), was
used to make S30 bacterial extract as described previously
(Amidi et al. 2010). A coupled in vitro transcription/
translation reaction mixture (further referred to as IVTT
mix), consisted of 30% (v/v) S30 extract, 175 lg/mL
tRNA, 250 lg/mL creatine kinase, 5.8 mM magnesium
acetate, 260U T7 polymerase, and 50% (v/v) low-
molecular-weight mix (LM mix) containing: 110 mM
HEPES, 3.4 mM DTT, 2.4 mM ATP, 1.6 mM CTP,
1.6 mM GTP, 1.6 mM UTP, 0.8 M creatine phosphate
(CP), 0.65 mM cAMP, 0.05 mM folinic acid, 0.21 M
potassium acetate, 27 mM ammonium acetate, 2 mM
each of the 20 amino acids, and 8% (v/v) PEG8000, was
used for protein synthesis. To initiate protein expression,
plasmid DNA was added to the IVTT mix at a ﬁnal
concentration of 20 nM and the reaction mixture was
incubated for 3 h at 30C.
Generation of b-galactosidase-producing AnExILs
AnExILs with b-galactosidase expressed inside liposomes
For preparation of AnExILs with b-galactosidase expressed
inside liposomes (further referred to as AnExIL-IN), 75 ll
of IVTT mixture and pIVEX2.2EM-LacZ with a ﬁnal
concentration of 20 nM, was used to rehydrate a batch of
6 lM of PEG-lipid cakes in order to form liposomes
encapsulating IVTT mix and pDNA. The liposomes were
incubated on ice for 10 min to complete the rehydration
process. To inactivate protein expression outside liposomes,
RNase with a ﬁnal concentration of 10 lg/ml, was added to
the liposomal suspension. Samples were incubated at 30C
for 3 h to allow protein synthesis to complete.
AnExILs with b-galactosidase attached
to the liposomal bilayer
To prepare b-galactosidase-bound onto Ni
2?-NTA lipo-
somes (further referred to as AnExIL-ON), b-galactosidase
was expressed in bulk and subsequently bound onto lipo-
somal bilayers as described below. Ninety-ll of IVTT and
pIVEX2.2EM-LacZ as a pDNA template with a ﬁnal
concentration of 20 nM was used for bulk expression of a
b-galactosidase with a C-terminal 6HIS-tag. IVTT mix
with DNA template was incubated at 30C for 3 h. After
the expression was completed, 75 ll of the reaction mix
containing expressed b-galactosidase was added to the
NTA-lipid cakes (6 lM lipids) and incubated for 10 min at
room temperature to form liposomes. The expressed
b-galactosidase has a 6-histidine residue which binds to
Ni
2? ions of Ni
2?-NTA liposomes. To remove the non
attached b-galactosidase, the liposomes were washed three
times with 0.5–1.5 ml phosphate buffer saline (PBS, NaCl
concentration was adjusted to make it isotonic with the
IVTT mix) by centrifugation at 8,000–9,0009g for 10 min
at 4C. After washing, the liposomes were re-suspended in
50 ll PBS.
Preparation of b-galactosidase-containing liposomes
An aqueous solution of b-galactosidase protein (40 IU/ml)
was prepared in PBS. Subsequently, 100 ll of each solution
was slowly added to freeze-dried lipids (6 lM) and incu-
bated for 10 min at room temperature until rehydration was
completed and liposomes were formed. To remove non-
encapsulated b-galactosidase, liposomes were washed three
times with PBS by centrifugation at 8,000–9,0009g for
10 min at 4C and re-suspended in 50 ll PBS. The amount
of encapsulated b-galactosidase in PEG-liposomes was
calculated from total amount of protein entrapped in
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galactosidase was co-entrapped with the b-galactosidase
enzyme at a concentration of 20 nM. The amount of
encapsulated b-galactosidase was measured based its
enzymatic activity.
Quantiﬁcation and antigenicity of the produced
b-galactosidase
b-galactosidase activity assay
The amount of encapsulated b-galactosidase as well as
expressed b-galactosidase in bulk, inside the PEG-lipo-
somes or bound onto Ni
2?-NTA liposomes were deter-
mined based on enzymatic activity of b-galactosidase using
ﬂuorescence spectroscopy (Amidi et al. 2010). Brieﬂy, in
this assay, FDG as a substrate was cleaved by b-galactosi-
dase into ﬂuorescein, and two galactose molecules in a two-
step reaction. By using high FDG concentrations relative to
enzyme concentrations, the concentration of formed b-
galactosidase could be directly deduced from the substrate
conversion rate as measured by an increase in ﬂuorescein
ﬂuorescence in time (excitation/emission wavelengths: 488/
512 nm). A calibration curve of 0–500 lg/ml (corre-
sponding to 0–200 IU/ml) of commercially available puri-
ﬁed E. coli b-galactosidase was used in all experiments.
To determine the amount of encapsulated b-galactosi-
dase or formed by IVTT in liposomes, 10 ll of each lipo-
some suspension was diluted in 90 ll Cell lytic B buffer
(Sigma, Saint Louis, MO, USA) to disrupt the liposomes
and release the produced protein. A same treatment was
done with a blank liposomal formulation and standards to
correct for possible interferences of lipid components and
Cell lytic B buffer with generated ﬂuorescent signal. Sub-
sequently 100 ll of substrate (FDG, 1 mM) was automati-
cally added to each sample and standard and generated
ﬂuorescent signal was measured every 0.5 s over a period of
120 s at 25C using a ﬂuorescent well-plate reader (FLU-
Ostar OPTIMA, BMG-Labtech, Offenburg, Germany). To
determine the concentration of encapsulated or expressed b-
galactosidase, initial substrate conversion slopes (relative
light unit (RLU)/s) were determined and compared to those
of standards with known concentrations of b-galactosidase
(Amidi et al. 2010).
Western blotting
Western blotting was done to evaluate the antigenicity of
the expressed b-galactosidase. Liposomes containing
b-galactosidase were disrupted by adding 100 ll of Cell
lytic B buffer to 55 ll of liposome suspension. After adding
electrophoresis loading-buffer (60 mM Tris–HCl, pH 6.8,
with 25% glycerol and 2% SDS containing 0.1% bromo-
phenol blue solution, and b-mercaptoethanol), the samples
were heated for 5 min at 95C and electrophoresed at 125 V
under reducing conditions, in a 10% SDS–polyacrylamide
gel (Bollag and Edelstein 1991). After gel electrophoresis,
antigen bands were transferred to a nitrocellulose mem-
brane by using a dry Western blotting system (iBlot,
Invitrogen, Frederick, MD) in 6 min. After blotting the free
sites were blocked with 1% non-fat milk-powder in PBS
containing 0.05% Tween 20 (PBS-T). Next, the membrane
was incubated with a solution of goat anti-b-galactosidase
polyclonal antibody in PBS-T containing 0.1% non-fat milk
powder. The membrane was then washed to remove the
unbound antibody and incubated with Cy-5-labeled, rabbit
IgG anti-goat immunoglobulin. The blotted antigen–anti-
body complexes were visualized by a ﬂuorescence using a
Typhoon imager (Amersham Corporation, Arlington
Heigths, IL, USA).
Immunization studies
Female Balb-c mice, 6–8 weeks old (Charles River,
Netherlands), were housed in groups of 5 and maintained in
the animal facility of Utrecht University with a 12 h day
and night schedule, while food and water were ad libitum.
The experiments were approved by the Ethical Committee
Table 1 Immunization study design; groups of 5 mice were immunized i.m. with the formulations indicated in the table
Formulation b-galactosidase
antigen dose
(mU)
a
Volume of
injection
(ll)
Immunization
schedule
(day)
Serum
sampling
(day)
1. AnExIL-IN: Expressed b-galactosidase inside PEG-liposomes 800 100 1, 14 1, 14, 28
2. AnExIL-ON: Expressed b-galactosidase attached to the surface of NTA liposomes 800 100 1, 14 1, 14, 28
3. Liposomal protein vaccine: Commercial b-galactosidase loaded PEG-liposomes 800 100 1, 14 1, 14, 28
4. Liposomal protein/DNA vaccine: Commercial b-galactosidase- and
pIVEX-LacZ loaded PEG-liposomes
800 100 1, 14 1, 14, 28
5. Liposomal DNA vaccine: Eukaryote pDNA, pCMV-LacZ loaded PEG-liposomes 0 100 1, 14 1, 14, 28
6. E-coli Tuner S30 extract loaded PEG-liposomes 0 100 1, 14 1, 14, 28
a 800 mU of b-galactosidase corresponds to approximately 2 lg of active b-galactosidase from a commercial source (Sigma)
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123for Animal Experimentation of Utrecht University. Mice
(5 per group) were intramuscularly (i.m.) immunized twice
with 2-week intervals. Mice received 100 ll of different
formulations (Table 1) divided over two batches of 50 ll
which were injected in each of the hind leg muscles. Before
each immunization and 2 weeks after the last immuniza-
tion, the mice were bled by cheek puncture and then sac-
riﬁced by inhalation of excess CO2. Individual serum
samples were separated from blood cells and coagulated
proteins by centrifugation for 5 min at 14,0009g and 4C,
and stored at -20C.
Antibody assays (ELISA)
b-galactosidase-speciﬁc antibody responses were deter-
mined by using an enzyme-linked immunosorbent assay
(ELISA). Brieﬂy, ELISA plates (high binding capacity,
Greiner, Alphen a/d Rijn, the Netherlands) were coated
overnight at ambient temperature with b-galactosidase
(100 ng in 100 ll/well) in coating buffer (0.05 M carbon-
ate/bicarbonate, pH 9.6). To measure antibody responses in
mice vaccinated with liposomes containing expressed
b-galactosidase, the ELISA plates were coated with
recombinantly produced b-galactosidase in E. coli strain
BL21 (DE3) (Invitrogen Carlsbad, CA) and puriﬁed by
using an Akta Puriﬁer equipped with 5 mL His–Trap HP
columns (GE Healthcare, Uppsala, Sweden). For serum
samples of mice vaccinated with control formulations
containing b-galactosidase encapsulated in liposomes, the
plates were coated with the same commercial source of
b-galactosidase that was used for entrapment. After coat-
ing, plates were washed and blocked by incubation with
2.5% (w/v) milk powder in coating buffer (200 ll/well) for
1 h at 37C. Subsequently, the plates were washed with
PBS containing 0.05% Tween, pH 7.4 (PBS/Tween).
Appropriate dilutions of sera of each individual mouse
were applied to the plates, serially diluted two-fold in PBS/
Tween and incubated for 2 h at 37C. Plates were then
washed and incubated either with horseradish peroxidase
(HRP)-conjugated goat antibody against mice IgG or HRP-
conjugated rabbit antibody against mice IgG1 or HRP-
conjugated rat antibody against mice IgG2a (all diluted
1:5000 in PBS/Tween, 100 ll/well) for 1 h at 37C.
Thereafter, the plates were washed twice with PBS/Tween
and once with PBS. Speciﬁc antibodies were detected by
adding 100 ll of 3,30,5,50-tetra methyl benzidine (TMB,
0.1 mg/ml) in 10 mM sodium acetate pH 5.5 buffer also
containing 0.06% (v/v) hydrogen peroxide to each well.
After 10 min, the reaction was stopped by adding 50 ll
2M H 2SO4 to each well. Total IgG, IgG1 and IgG2a
antibody titers are expressed as the reciprocal sample
dilution corresponding with an A450 of 0.2 above the
background (Amidi et al. 2007). Comparison between mice
of different groups with positive titers was made by a one-
way ANOVA test.
Results
Characterization of AnExILs and liposomes loaded
with b-galactosidase and/or pDNA
Cell-free protein synthesis was used to transcribe and
translate the lacZ gene encoding for E. coli b-galactosidase
either in bulk, inside liposomal compartments (AnExILs-
IN) or adhered onto the surface of liposomes (AnExIL-ON)
(For details of liposome preparation see materials & meth-
ods section). The volume-weighted mean diameter of
b-galactosidase-loadedliposomesandAnExILformulations
wasapproximately1.5 lm.Thedoseofb-galactosidasewas
standardizedto800 mUperformulation(see‘‘Materialsand
methods’’), which corresponds to approximately 2 lgo f
active b-galactosidase from a commercial source (Sigma).
The S30 extract used for IVTT was derived from E. coli
BL21 Tuner
TM strain, which is devoid of endogenous
b-galactosidase. This is important to avoid interference of
endogenousb-galactosidaseintheexperiments(Amidietal.
2010). SDS–PAGE and Western blot analysis of S30 extract
made from E-coli Tuner
TM strain proved absence of
endogenous b-galactosidase in S30 extract (Fig. 2). Impor-
tantly, Western blot analysis conﬁrmed that the expressed
b-galactosidase was recognized by polyvalent anti-b-
galactosidase antibodies and the antigenicity of b-galacto-
sidase was preserved in IVTT mix (Fig. 2).
Fig. 2 Determination of b-galactosidase expression by Western
blotting under reducing conditions. lane1: S30 extract without
DNA; lane 2: expressed b-galactosidase in IVTT mix; lane 3:
expressed b-galactosidase after IMAC puriﬁcation; lane 4: b-galac-
tosidase from commercial source
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in mice
To investigate the potency of AnExILs as alternatives for
conventional protein or DNA vaccines, we compared sys-
temic humoral responses of mice immunized i.m. with
AnExIL-IN, AnExIL-ON, pCMV-Lac-Z encapsulated in
liposomes (further referred to as liposomal DNA vaccine),
b-galactosidase encapsulated in liposomes (further referred
to as liposomal protein vaccines) and b-galactosidase co-
encapsulated with pDNA (pIVEX-Lac-Z) in liposomes
(further referred to as liposomal protein/DNA vaccines).
The liposomal DNA vaccine was poorly immunogenic and
induced very low serum IgG titers in only some of the
vaccinated animals after single dose i.m. immunization
(Fig. 3a). In contrast, AnExIL-IN induced high serum
antibody responses after i.m. immunization, which were
signiﬁcantly higher than those achieved after i.m. injection
of liposomal protein and liposomal protein/DNA vaccines
(Fig. 3b) (P\0.001). Single i.m. vaccination with
AnExIL-ON could elicit substantially higher serum anti-
body responses than those elicited by other vaccines
(Fig. 3a, b) (P\0.001). It has been shown that surface-
linked liposomal antigens could enhance presentation of
antigens to APCs and induce stronger immune responses
(Taneichi et al. 2006a; Naito et al. 1996; Uchida and
Taneichi 2008). Altogether, these results point to strong
immunostimulating effects of AnExIL vaccines and robust
impact of surface antigen presentation on systemic anti-
body response. Since there are usually needs for booster
vaccinations in order to induce prolonged and strong
immune responses, the effect of a booster immunization on
the systemic antibody production was studied in mice.
After booster immunizations all group of mice showed
higher IgG titers but not signiﬁcantly higher than those
after prime immunization (Fig. 3).
To exclude that the observed anti-b-galactosidase serum
titers were induced by components within the S30 bacterial
extract, serum antibody titers of mice injected with
AnExILs without the pDNA encoding b-galactosidase
were measured. After i.m. immunizations with pDNA-
lacking AnExILs, mice showed a negligible b-galactosi-
dase speciﬁc antibody response (Fig. 3b). This clearly
indicates that the antigen speciﬁc immune response is
exclusively mediated by the genetic input.
To gain more insight into the nature and quality of the
systemic immune response, IgG1 and IgG2a subclasses of
b-galactosidase-speciﬁc antibodies (Fig. 4a, b) were deter-
mined. After i.m. immunizations with liposomal DNA
vaccine, there were no detectable levels of IgG1 or IgG2a in
the sera of the vaccinated mice. As compared to liposomal
protein and protein/DNA vaccines, AnExIL-IN and the
AnExIL-ON vaccines showed superior IgG1 (P\0.05)
and IgG2a (P\0.001) responses and those induced by
AnExIL-ON was the highest (Fig. 4a, b). The IgG1 and
IgG2a responses of control and tested formulations largely
corresponded to the total IgG responses (Fig. 4a, b).
Remarkably, the AnExIL-ON induced signiﬁcantly higher
IgG2a antibody levels (Fig. 4a) and consequently notably
higher IgG2a/IgG1 ratios after booster vaccination com-
pared to the other formulations (Fig. 4d).
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Fig. 3 Serum anti-b-galactosidase antigen-speciﬁc total serum IgG
responses in mice immunized i.m. with AnExIL-IN, AnExIL-ON,
liposomal DNA vaccine (Lipo’s DNA vac) (a), liposomal protein
vaccine (Lipo’s protein vac), liposomal protein/DNA vaccine (Lipo’s
protein/DNA vac) and liposomal S30 extract (Lipo’s S30 extract) (b).
Sera were collected 14 days after each immunization. Antibody titers
are expressed as mean of the responding mice; the bars represent the
95% conﬁdence intervals. The numbers above the columns indicate
the number of responders per group. Asterisks indicate titers that are
signiﬁcantly (* P\0.05; ** P\0.001) higher than those of the
group immunized (booster vaccination) with liposomal protein/DNA
vaccines. Circles indicate titers that are signiﬁcantly ( P\0.05)
higher than those of the group immunized (booster vaccination) with
AnExIL-IN
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123Discussion
The results presented here demonstrate that AnExILs can
be used as a synthetic biology platform to construct vac-
cines which can be genetically programmed in order to
obtain antigen-speciﬁcity. AnExILs mimic characteristics
of natural pathogens, without being virulent, and were able
to induce strong humoral immune responses.
The particle size of AnExILs is amenable for uptake by
antigen presenting cells (Foged et al. 2005; Tabata et al.
1996; Xiang et al. 2006; Yoshida and Babensee 2006). The
amount of pIVEX2.2EM-LacZ-6HIS encapsulated in lip-
osomes (20 nM) was sufﬁcient to initiate in vitro protein
expression in liposomal compartments. b-galactosidase
was successfully produced and quantiﬁed in liposomes.
Enzymatic activity was used as a fast and sensitive method
for evaluating biological activity and quantiﬁcation of
expressed b-galactosidase in AnExILs and showed that the
produced enzyme has a correct folding and is active in cell-
free protein synthesis. Western blot analysis showed that
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Fig. 4 Serum anti-b-galactosidase antigen-speciﬁc total serum IgG2a
(a) and IgG1 (b) responses and corresponding IgG2a/IgG1 ratios
(prime vaccination c) and (booster vaccination d) of mice immunized
i.m. with AnExIL-IN, AnExIL-ON, liposomal DNA vaccine (Lipo’s
DNA vac), liposomal protein vaccine (Lipo’s protein vac) and
liposomal protein/DNA vaccine (Lipo’s protein/DNA vac). Sera were
collected 14 days after each immunization. Antibody titers are
expressed as mean of the responding mice; the bars represent the
95% conﬁdence intervals. The numbers above the columns indicate
the number of responders per group. Asterisks indicate titers that are
signiﬁcantly (* P\0.05; ** P\0.001) higher than those of the
group immunized (booster vaccination) with liposomal protein/DNA
vaccines. Circles indicate titers that are signiﬁcantly ( P\0.05)
higher than those of the group immunized (booster vaccination) with
AnExIL-IN
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123antigenicity of the expressed b-galactosidase was pre-
served. These results indicate that cell-free protein syn-
thesis can efﬁciently produce antigens avoiding complexity
and maintenance of cell viability associated with recom-
binant and in vivo systems (Jewett et al. 2008). Further-
more, it was demonstrated that the use of AnExILs can
circumvent current problems of low immunogenicity with
non-adjuvanted DNA vaccines (Liu and Ulmer 2005;
Rosenberg et al. 2003; Trimble et al. 2009). As opposed to
i.m. vaccination with liposomal DNA vaccine, i.m.
immunization with AnExILs resulted in strong humoral
immune responses. This result is in agreement with other
studies showing that DNA vaccination is incapable of
inducing strong antibody responses most probably because
of poor transfection of DNA in endogenous cells, which
leads to low doses of antigens produced (Abdulhaqq and
Weiner 2008;L u2008). Moreover, AnExILs were able to
induce signiﬁcantly higher antibody responses as compared
to conventional liposomes encapsulating antigen with or
without pDNA. These results demonstrate strong immu-
nostimulating effect of AnExILs as alternative for DNA
and protein vaccines. Factors that might contribute to the
adjuvant effect of AnExILs include efﬁcient delivery of
antigen to APCs, possible adjuvant activities of pDNA (due
to CpG methylation pattern) (Klinman et al. 2009) and the
presence of pathogen-associated molecular patterns
(PAMPs) in the bacterial S30 extract which can activate the
innate immune system via pattern recognition receptors.
AnExIL-ON with surfaced-linked b-galactosidase was
tested in mice as an alternative to AnExIL-IN formulation,
in which antigen is entrapped inside vesicles. From the
results of the vaccination studies with AnExIL-ON, it can
be concluded that antigen presentation on the surface of the
liposomes could signiﬁcantly enhance systemic immune
responses as compared to the other tested formulations and
even a single immunization was sufﬁcient to strongly
stimulate an immune response superior to those achieved
after i.m. immunization with conventional liposomal vac-
cines. Several studies have previously shown that surface-
linked liposomal antigens could enhance presentation of
antigens to APCs and induce stronger immune responses
(Kohyama et al. 2009; Matsui et al. 2010; Ohno et al. 2009;
Takagi et al. 2009; Taneichi et al. 2006b).
The impact of the AnExILs and other control vaccines
on the antibody subtype proﬁle was also investigated. In
most of infectious diseases protection against viral or
bacterial infections are mainly mediated by neutralizing
immunoglobulins that bind to the viral or bacterial antigens
(Gissmann 2009; Ho et al. 2002; Monteﬁori et al. 2007;
Monteﬁori and Mascola 2009; Sattentau 2008; Smith
2009). In mice IgG1 and IgG2a antibodies are known to
contribute to virus neutralization. IgG2a has been reported
to contribute in complement activation and antibody-
dependent cell-mediated immunity and is more effective
than IgG1 in protection against viral infections by pre-
venting virus replication (Coutelier et al. 1987; Hocart
et al. 1989). On the other hand, the absolute concentration
of IgG is important for reducing the viral shedding (Hocart
et al. 1989; Hovden et al. 2005). Therefore, induction of a
combined IgG2a/IgG1 (T-helper1/T-helper2) response may
improve vaccine efﬁcacy especially against viral infec-
tions. In this study, i.m. immunizations with all vaccines
resulted in a mixed Th1/Th2 immune response and i.m.
administered AnExILs were able to markedly enhance both
the IgG1 and the IgG2a response after i.m. vaccination as
compared to protein and DNA liposomal formulations
(Fig. 4a, b), which may be advantageous for protection
against viral or intracellular bacterial infections. The
IgG2a/IgG1 ratio of AnExIL-IN was the highest among
those of other vaccines after prime vaccination (Fig. 4c)
and that of AnExIL-ON was substantially increased after
booster immunization (Fig. 4d). These data suggest that the
quality of the immune response to b-galactosidase vaccine
is substantially affected by the characteristic of AnExIL
formulations.
The work presented here shows for the ﬁrst time that
liposomes can be used as antigen-producing artiﬁcial-cells
for vaccination. AnExILs combine antigen-production,
delivery and adjuvanticity in one system, making them
more potent in inducing antibody responses compared to
liposomal DNA vaccines as shown here. Still, the speci-
ﬁcity of AnExILs is only determined by its genetic input
which offers great ﬂexibility in vaccine production and
formulation. Preliminary data from our lab show that it is
possible to store AnExILs lyophilized. Upon hydration
with a DNA solution, the DNA is being transcribed and
translated inside the rehydrated liposomes (data not
shown). Such a universal vaccine platform may solve some
of the problems of production lag-time with conventional
vaccines (Hinman et al. 2006; DesRoches et al. 2005;
Ulmer et al. 2006). Furthermore, it may allow easy pro-
duction of personalized vaccines for e.g. cancer vaccina-
tion, in which the antigens are optimized for each
individual (Poland et al. 2008).
Although not tested here, the injection of bacterial
components as essential part of the AnExIL formulation
may pose problems of reactogenicity. S30 extract derived
from E. coli is an essential component of AnExILs and
which is likely to contain the pyrogenic endotoxin LPS.
Visual inspection of the mice after i.m. administration of
the AnExILs did not show any discomfort or illness.
Nevertheless, alternative sources of IVTT mixes that are
free of endotoxins should be tested. For example, extracts
prepared from gram-positive bacteria, wheat germ or the
synthetic PURExpress system (Shimizu et al. 2001) may be
substituted for the E. coli-based extract.
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123Although we have only used a single antigen to show
proof-of-concept of our AnExIL vaccination platform,
mixtures of antigens can be expressed inside AnExILs by
simply mixing pDNAs encoding different antigens.
Although different antigens will have different levels of
expression in cell-free expression systems, in general, the
expression levels are high enough for the purpose of vac-
cination, where only microgram quantities of proteins are
required. In fact, membrane proteins which are often dif-
ﬁcult to produce in bacteria show remarkably high levels of
expression in prokaryotic cell-free systems in the presence
of liposomes (Junge et al. 2010; Goren et al. 2009; Kuruma
et al. 2010; Moritani et al. 2010; Nozawa et al. 2010;
Reckel et al. 2010). Besides DNA encoding antigens, a
variety of genetic inputs can be used in order to control the
type of immune response provoked. For example, genetic
adjuvants, such as chemokines or cytokines may be co-
expressed inside the AnExILs in order to enhance the
inﬂux of immune cells at the site of injection and uptake of
AnExILs by antigen presenting cells. As such AnExILs
form an excellent synthetic biology platform for genetic
programming using standard biological parts (Canton et al.
2008; Knight 2003).
In conclusion, we have shown proof-of-concept for a
genetically programmable vaccine based on the in situ
production of antigens from DNA templates. Further
immunization studies focusing on co-administering of
DNAs, encoding biologically relevant antigens and genetic
adjuvants (e.g. cytokines) are needed to demonstrate the
possibilities and limits of the AnExIL vaccination platform.
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